Plasma zinc status and hyperinflammatory syndrome in hospitalized COVID-19 patients: An observational study
•The majority of hospitalized COVID-19 patients are zinc deficient.•There is a weak correlation between plasma zinc and the length of hospital stay.•cHIS score, described by Webb et al., is externally validated in this study.•Current findings do not support plasma zinc as a robust prognostic factor....
Gespeichert in:
| Veröffentlicht in: | International immunopharmacology 2021-11, Vol.100, p.108163-108163, Article 108163 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 108163 |
|---|---|
| container_issue | |
| container_start_page | 108163 |
| container_title | International immunopharmacology |
| container_volume | 100 |
| creator | Verschelden, Gil Noeparast, Maxim Noparast, Maryam Goossens, Mathijs Christiaan Lauwers, Maïlis Cotton, Frédéric Michel, Charlotte Goyvaerts, Cleo Hites, Maya |
| description | •The majority of hospitalized COVID-19 patients are zinc deficient.•There is a weak correlation between plasma zinc and the length of hospital stay.•cHIS score, described by Webb et al., is externally validated in this study.•Current findings do not support plasma zinc as a robust prognostic factor.
Zinc deficiency is associated with impaired antiviral response, cytokine releasing syndrome (CRS), and acute respiratory distress syndrome. Notably, similar complications are being observed during severe SARS-CoV-2 infection.
We conducted a prospective, single-center, observational study in a tertiary university hospital (CUB-Hôpital Erasme, Brussels) to address the zinc status, the association between the plasma zinc concentration, development of CRS, and the clinical outcomes in PCR-confirmed and hospitalized COVID-19 patients.
One hundred and thirty-nine eligible patients were included between May 2020 and November 2020 (median age of 65 years [IQR = 54, 77]).
Our cohort's median plasma zinc concentration was 57 µg/dL (interquartile range [IQR] = 45, 67) compared to 74 µg/dL (IQR = 64, 84) in the retrospective non-COVID-19 control group (N = 1513; p |
| doi_str_mv | 10.1016/j.intimp.2021.108163 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8450071</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1567576921007992</els_id><sourcerecordid>2577733631</sourcerecordid><originalsourceid>FETCH-LOGICAL-c557t-9939acc6cdc40ea1157ca6f3698393370ac7ae3930c4c100ce78d8af08851acd3</originalsourceid><addsrcrecordid>eNp9kU9v1DAQxS1ERUvhGyBkiUsvWew4jh0OSNXyr1Kl9gBcrantsF4SO9jOSumnx6stBXroyaPxm-d5_iH0ipIVJbR9u105n904rWpS09KStGVP0AmVQlZUEP601LwVFRdtd4yep7QlpPQb-gwds4ZLRuv6BP28HiCNgG-d1zhlyHPC4A3eLJONzvcDjCPkEBecFm9iGC12Hm9CmlyGwd1ag9dX3y8-VLTDE2RnfU7v8LnH4SbZuCud4GEozrNZXqCjHoZkX96dp-jbp49f11-qy6vPF-vzy0pzLnLVdawDrVttdEMsUMqFhrZnbSdZx5ggoAXYUhLdaEqItkIaCT2RklPQhp2i9wffab4ZrdFlpwiDmqIbIS4qgFP_33i3UT_CTsmGEyJoMTi7M4jh12xTVqNL2g4DeBvmpGouhGCsZXvpmwfSbZhjiVxULeGMNIyzomoOKh1DStH298tQovY01VYdaKo9TXWgWcZe_xvkfugPvr9JbfnOnbNRJV0QaGtctDorE9zjL_wG2D60bQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2605304353</pqid></control><display><type>article</type><title>Plasma zinc status and hyperinflammatory syndrome in hospitalized COVID-19 patients: An observational study</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Verschelden, Gil ; Noeparast, Maxim ; Noparast, Maryam ; Goossens, Mathijs Christiaan ; Lauwers, Maïlis ; Cotton, Frédéric ; Michel, Charlotte ; Goyvaerts, Cleo ; Hites, Maya</creator><creatorcontrib>Verschelden, Gil ; Noeparast, Maxim ; Noparast, Maryam ; Goossens, Mathijs Christiaan ; Lauwers, Maïlis ; Cotton, Frédéric ; Michel, Charlotte ; Goyvaerts, Cleo ; Hites, Maya</creatorcontrib><description>•The majority of hospitalized COVID-19 patients are zinc deficient.•There is a weak correlation between plasma zinc and the length of hospital stay.•cHIS score, described by Webb et al., is externally validated in this study.•Current findings do not support plasma zinc as a robust prognostic factor.
Zinc deficiency is associated with impaired antiviral response, cytokine releasing syndrome (CRS), and acute respiratory distress syndrome. Notably, similar complications are being observed during severe SARS-CoV-2 infection.
We conducted a prospective, single-center, observational study in a tertiary university hospital (CUB-Hôpital Erasme, Brussels) to address the zinc status, the association between the plasma zinc concentration, development of CRS, and the clinical outcomes in PCR-confirmed and hospitalized COVID-19 patients.
One hundred and thirty-nine eligible patients were included between May 2020 and November 2020 (median age of 65 years [IQR = 54, 77]).
Our cohort's median plasma zinc concentration was 57 µg/dL (interquartile range [IQR] = 45, 67) compared to 74 µg/dL (IQR = 64, 84) in the retrospective non-COVID-19 control group (N = 1513; p < 0.001). Markedly, the absolute majority of COVID-19 patients (96%) were zinc deficient (<80 µg/dL).
The median zinc concentration was lower in patients with CRS compared to those without CRS (-5 µg/dL; 95% CI = -10.5, 0.051; p = 0.048).
Among the tested outcomes, zinc concentration is significantly correlated with only the length of hospital stay (rho = -0.19; p = 0.022), but not with mortality or morbidity. As such, our findings do not support the role of zinc as a robust prognostic marker among hospitalized COVID-19 patients who in our cohort presented a high prevalence of zinc deficiency. It might be more beneficial to explore the role of zinc as a biomarker for assessing the risk of developing a tissue-damaging CRS and predicting outcomes in patients diagnosed with COVID-19 at the early stage of the disease.</description><identifier>ISSN: 1567-5769</identifier><identifier>EISSN: 1878-1705</identifier><identifier>DOI: 10.1016/j.intimp.2021.108163</identifier><identifier>PMID: 34583122</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Aged ; Biomarkers ; cHIS ; Complications ; Coronaviruses ; COVID-19 ; COVID-19 - blood ; COVID-19 - complications ; Cytokine Release Syndrome - blood ; Cytokine Release Syndrome - etiology ; Cytokines ; Female ; Hospitalization ; Humans ; Inflammation ; Male ; Middle Aged ; Morbidity ; Nutrient deficiency ; Observational studies ; Patients ; Prospective Studies ; Respiratory distress syndrome ; SARS-CoV-2 ; Severe acute respiratory syndrome coronavirus 2 ; Viral diseases ; Zinc ; Zinc - blood ; Zinc - physiology</subject><ispartof>International immunopharmacology, 2021-11, Vol.100, p.108163-108163, Article 108163</ispartof><rights>2021 Elsevier B.V.</rights><rights>Copyright © 2021 Elsevier B.V. All rights reserved.</rights><rights>Copyright Elsevier BV Nov 2021</rights><rights>2021 Elsevier B.V. All rights reserved. 2021 Elsevier B.V.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c557t-9939acc6cdc40ea1157ca6f3698393370ac7ae3930c4c100ce78d8af08851acd3</citedby><cites>FETCH-LOGICAL-c557t-9939acc6cdc40ea1157ca6f3698393370ac7ae3930c4c100ce78d8af08851acd3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S1567576921007992$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,776,780,881,3537,27901,27902,65534</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34583122$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Verschelden, Gil</creatorcontrib><creatorcontrib>Noeparast, Maxim</creatorcontrib><creatorcontrib>Noparast, Maryam</creatorcontrib><creatorcontrib>Goossens, Mathijs Christiaan</creatorcontrib><creatorcontrib>Lauwers, Maïlis</creatorcontrib><creatorcontrib>Cotton, Frédéric</creatorcontrib><creatorcontrib>Michel, Charlotte</creatorcontrib><creatorcontrib>Goyvaerts, Cleo</creatorcontrib><creatorcontrib>Hites, Maya</creatorcontrib><title>Plasma zinc status and hyperinflammatory syndrome in hospitalized COVID-19 patients: An observational study</title><title>International immunopharmacology</title><addtitle>Int Immunopharmacol</addtitle><description>•The majority of hospitalized COVID-19 patients are zinc deficient.•There is a weak correlation between plasma zinc and the length of hospital stay.•cHIS score, described by Webb et al., is externally validated in this study.•Current findings do not support plasma zinc as a robust prognostic factor.
Zinc deficiency is associated with impaired antiviral response, cytokine releasing syndrome (CRS), and acute respiratory distress syndrome. Notably, similar complications are being observed during severe SARS-CoV-2 infection.
We conducted a prospective, single-center, observational study in a tertiary university hospital (CUB-Hôpital Erasme, Brussels) to address the zinc status, the association between the plasma zinc concentration, development of CRS, and the clinical outcomes in PCR-confirmed and hospitalized COVID-19 patients.
One hundred and thirty-nine eligible patients were included between May 2020 and November 2020 (median age of 65 years [IQR = 54, 77]).
Our cohort's median plasma zinc concentration was 57 µg/dL (interquartile range [IQR] = 45, 67) compared to 74 µg/dL (IQR = 64, 84) in the retrospective non-COVID-19 control group (N = 1513; p < 0.001). Markedly, the absolute majority of COVID-19 patients (96%) were zinc deficient (<80 µg/dL).
The median zinc concentration was lower in patients with CRS compared to those without CRS (-5 µg/dL; 95% CI = -10.5, 0.051; p = 0.048).
Among the tested outcomes, zinc concentration is significantly correlated with only the length of hospital stay (rho = -0.19; p = 0.022), but not with mortality or morbidity. As such, our findings do not support the role of zinc as a robust prognostic marker among hospitalized COVID-19 patients who in our cohort presented a high prevalence of zinc deficiency. It might be more beneficial to explore the role of zinc as a biomarker for assessing the risk of developing a tissue-damaging CRS and predicting outcomes in patients diagnosed with COVID-19 at the early stage of the disease.</description><subject>Aged</subject><subject>Biomarkers</subject><subject>cHIS</subject><subject>Complications</subject><subject>Coronaviruses</subject><subject>COVID-19</subject><subject>COVID-19 - blood</subject><subject>COVID-19 - complications</subject><subject>Cytokine Release Syndrome - blood</subject><subject>Cytokine Release Syndrome - etiology</subject><subject>Cytokines</subject><subject>Female</subject><subject>Hospitalization</subject><subject>Humans</subject><subject>Inflammation</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Morbidity</subject><subject>Nutrient deficiency</subject><subject>Observational studies</subject><subject>Patients</subject><subject>Prospective Studies</subject><subject>Respiratory distress syndrome</subject><subject>SARS-CoV-2</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><subject>Viral diseases</subject><subject>Zinc</subject><subject>Zinc - blood</subject><subject>Zinc - physiology</subject><issn>1567-5769</issn><issn>1878-1705</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kU9v1DAQxS1ERUvhGyBkiUsvWew4jh0OSNXyr1Kl9gBcrantsF4SO9jOSumnx6stBXroyaPxm-d5_iH0ipIVJbR9u105n904rWpS09KStGVP0AmVQlZUEP601LwVFRdtd4yep7QlpPQb-gwds4ZLRuv6BP28HiCNgG-d1zhlyHPC4A3eLJONzvcDjCPkEBecFm9iGC12Hm9CmlyGwd1ag9dX3y8-VLTDE2RnfU7v8LnH4SbZuCud4GEozrNZXqCjHoZkX96dp-jbp49f11-qy6vPF-vzy0pzLnLVdawDrVttdEMsUMqFhrZnbSdZx5ggoAXYUhLdaEqItkIaCT2RklPQhp2i9wffab4ZrdFlpwiDmqIbIS4qgFP_33i3UT_CTsmGEyJoMTi7M4jh12xTVqNL2g4DeBvmpGouhGCsZXvpmwfSbZhjiVxULeGMNIyzomoOKh1DStH298tQovY01VYdaKo9TXWgWcZe_xvkfugPvr9JbfnOnbNRJV0QaGtctDorE9zjL_wG2D60bQ</recordid><startdate>20211101</startdate><enddate>20211101</enddate><creator>Verschelden, Gil</creator><creator>Noeparast, Maxim</creator><creator>Noparast, Maryam</creator><creator>Goossens, Mathijs Christiaan</creator><creator>Lauwers, Maïlis</creator><creator>Cotton, Frédéric</creator><creator>Michel, Charlotte</creator><creator>Goyvaerts, Cleo</creator><creator>Hites, Maya</creator><general>Elsevier B.V</general><general>Elsevier BV</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>7T5</scope><scope>7U7</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>P64</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20211101</creationdate><title>Plasma zinc status and hyperinflammatory syndrome in hospitalized COVID-19 patients: An observational study</title><author>Verschelden, Gil ; Noeparast, Maxim ; Noparast, Maryam ; Goossens, Mathijs Christiaan ; Lauwers, Maïlis ; Cotton, Frédéric ; Michel, Charlotte ; Goyvaerts, Cleo ; Hites, Maya</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c557t-9939acc6cdc40ea1157ca6f3698393370ac7ae3930c4c100ce78d8af08851acd3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Aged</topic><topic>Biomarkers</topic><topic>cHIS</topic><topic>Complications</topic><topic>Coronaviruses</topic><topic>COVID-19</topic><topic>COVID-19 - blood</topic><topic>COVID-19 - complications</topic><topic>Cytokine Release Syndrome - blood</topic><topic>Cytokine Release Syndrome - etiology</topic><topic>Cytokines</topic><topic>Female</topic><topic>Hospitalization</topic><topic>Humans</topic><topic>Inflammation</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Morbidity</topic><topic>Nutrient deficiency</topic><topic>Observational studies</topic><topic>Patients</topic><topic>Prospective Studies</topic><topic>Respiratory distress syndrome</topic><topic>SARS-CoV-2</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><topic>Viral diseases</topic><topic>Zinc</topic><topic>Zinc - blood</topic><topic>Zinc - physiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Verschelden, Gil</creatorcontrib><creatorcontrib>Noeparast, Maxim</creatorcontrib><creatorcontrib>Noparast, Maryam</creatorcontrib><creatorcontrib>Goossens, Mathijs Christiaan</creatorcontrib><creatorcontrib>Lauwers, Maïlis</creatorcontrib><creatorcontrib>Cotton, Frédéric</creatorcontrib><creatorcontrib>Michel, Charlotte</creatorcontrib><creatorcontrib>Goyvaerts, Cleo</creatorcontrib><creatorcontrib>Hites, Maya</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Immunology Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>International immunopharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Verschelden, Gil</au><au>Noeparast, Maxim</au><au>Noparast, Maryam</au><au>Goossens, Mathijs Christiaan</au><au>Lauwers, Maïlis</au><au>Cotton, Frédéric</au><au>Michel, Charlotte</au><au>Goyvaerts, Cleo</au><au>Hites, Maya</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Plasma zinc status and hyperinflammatory syndrome in hospitalized COVID-19 patients: An observational study</atitle><jtitle>International immunopharmacology</jtitle><addtitle>Int Immunopharmacol</addtitle><date>2021-11-01</date><risdate>2021</risdate><volume>100</volume><spage>108163</spage><epage>108163</epage><pages>108163-108163</pages><artnum>108163</artnum><issn>1567-5769</issn><eissn>1878-1705</eissn><abstract>•The majority of hospitalized COVID-19 patients are zinc deficient.•There is a weak correlation between plasma zinc and the length of hospital stay.•cHIS score, described by Webb et al., is externally validated in this study.•Current findings do not support plasma zinc as a robust prognostic factor.
Zinc deficiency is associated with impaired antiviral response, cytokine releasing syndrome (CRS), and acute respiratory distress syndrome. Notably, similar complications are being observed during severe SARS-CoV-2 infection.
We conducted a prospective, single-center, observational study in a tertiary university hospital (CUB-Hôpital Erasme, Brussels) to address the zinc status, the association between the plasma zinc concentration, development of CRS, and the clinical outcomes in PCR-confirmed and hospitalized COVID-19 patients.
One hundred and thirty-nine eligible patients were included between May 2020 and November 2020 (median age of 65 years [IQR = 54, 77]).
Our cohort's median plasma zinc concentration was 57 µg/dL (interquartile range [IQR] = 45, 67) compared to 74 µg/dL (IQR = 64, 84) in the retrospective non-COVID-19 control group (N = 1513; p < 0.001). Markedly, the absolute majority of COVID-19 patients (96%) were zinc deficient (<80 µg/dL).
The median zinc concentration was lower in patients with CRS compared to those without CRS (-5 µg/dL; 95% CI = -10.5, 0.051; p = 0.048).
Among the tested outcomes, zinc concentration is significantly correlated with only the length of hospital stay (rho = -0.19; p = 0.022), but not with mortality or morbidity. As such, our findings do not support the role of zinc as a robust prognostic marker among hospitalized COVID-19 patients who in our cohort presented a high prevalence of zinc deficiency. It might be more beneficial to explore the role of zinc as a biomarker for assessing the risk of developing a tissue-damaging CRS and predicting outcomes in patients diagnosed with COVID-19 at the early stage of the disease.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>34583122</pmid><doi>10.1016/j.intimp.2021.108163</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1567-5769 |
| ispartof | International immunopharmacology, 2021-11, Vol.100, p.108163-108163, Article 108163 |
| issn | 1567-5769 1878-1705 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8450071 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete |
| subjects | Aged Biomarkers cHIS Complications Coronaviruses COVID-19 COVID-19 - blood COVID-19 - complications Cytokine Release Syndrome - blood Cytokine Release Syndrome - etiology Cytokines Female Hospitalization Humans Inflammation Male Middle Aged Morbidity Nutrient deficiency Observational studies Patients Prospective Studies Respiratory distress syndrome SARS-CoV-2 Severe acute respiratory syndrome coronavirus 2 Viral diseases Zinc Zinc - blood Zinc - physiology |
| title | Plasma zinc status and hyperinflammatory syndrome in hospitalized COVID-19 patients: An observational study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-13T09%3A09%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Plasma%20zinc%20status%20and%20hyperinflammatory%20syndrome%20in%20hospitalized%20COVID-19%20patients:%20An%20observational%20study&rft.jtitle=International%20immunopharmacology&rft.au=Verschelden,%20Gil&rft.date=2021-11-01&rft.volume=100&rft.spage=108163&rft.epage=108163&rft.pages=108163-108163&rft.artnum=108163&rft.issn=1567-5769&rft.eissn=1878-1705&rft_id=info:doi/10.1016/j.intimp.2021.108163&rft_dat=%3Cproquest_pubme%3E2577733631%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2605304353&rft_id=info:pmid/34583122&rft_els_id=S1567576921007992&rfr_iscdi=true |